Open Access

The quest for fragile X biomarkers

Molecular and Cellular Pediatrics20141:1

DOI: 10.1186/s40348-014-0001-3

Received: 18 June 2014

Accepted: 4 September 2014

Published: 4 September 2014

Abstract

Background

Fragile X is the most common form of inherited intellectual disability and the leading known genetic cause of autism. There is currently no cure or approved medication for fragile X although various drugs target specific disease symptoms and a large number of therapeutics are in various stages of clinical development. Multiple recent clinical trials have failed on their primary endpoints indicating that there is a compelling need for validated biomarkers and outcome measures in fragile X.

Findings

There are currently no validated blood-based biomarkers to assess disease severity or to monitor drug efficacy in fragile X syndrome. Herein, we review candidate blood protein biomarkers including extracellular-regulated kinase, phosphoinositide 3-kinase, matrix metalloproteinase 9, amyloid-beta and amyloid-beta protein precursor.

Conclusions

Bench-to-bedside plans for fragile X syndrome are severely limited by the lack of validated outcome measures. The reviewed candidate biomarkers are at early stages of validation and deserve further investigation.

Keywords

Fragile X syndrome Biomarker Extracellular-regulated kinase Phosphoinositide 3-kinase Matrix metalloproteinase 9 Amyloid beta protein precursor Amyloid-beta

Introduction

A biomarker is a measurable and quantifiable biological characteristic that can serve as an indicator of healthy or pathological processes. For example, HDL and LDL are biomarkers for cardiovascular health and autoantibodies are biomarkers for autoimmune disease. Biomarkers are extremely useful in evaluating the clinical benefit of pharmaceutical interventions. A good biomarker assay will be sensitive, specific, rapid, simple to perform, inexpensive and applicable to easily obtained sample material. There is an urgent need to develop such biomarkers for fragile X syndrome (FXS).

Fragile X syndrome

FXS is the most common form of inherited mental retardation with a frequency of 1 in 2,500 births [1]. FXS results from a mutation in the fragile X mental retardation-1 (FMR1) gene, which was discovered by Drs. Ben Oostra, David Nelson and Stephen Warren in 1991. The FMR1 gene codes for fragile X mental retardation protein (FMRP), an RNA binding protein that plays a critical role in dendrite development. Thus, the absence of FMRP in FXS has a profound effect on synaptic plasticity. The clinical symptoms of FXS include intellectual disability, attention deficit and hyperactivity, anxiety, autistic behaviors, sensory integration problems, speech delay, seizures, hyperextensible joints, hypotonia, postpubescent macroorchidism, flat feet and vertical maxillary excess with protruding ears [2]. There is currently no cure or approved medication for FXS although various drugs target specific disease symptoms and a large number of therapeutics are in various stages of clinical development.

The compelling need for validated FXS biomarkers

Dr. Mark Bear and colleagues proposed the “mGluR Theory of FXS” in 2004 in which they provided a framework through which overactive signaling through group 1 metabotropic glutamate receptors (mGluRs) (mGluR1 and mGluR5) could contribute to the psychiatric and neurological symptoms of FXS [3]. Mechanistic research the past decade has validated the role of mGluR5 in FXS as well as identified additional membrane receptors, signaling molecules and proteins involved in long-term depression (LTD) that are potential therapeutic targets and disease biomarkers. Compounds targeting these molecules have moved into clinical trials in individuals with FXS, which has provided valuable information regarding potential drug efficacy; however, bench-to-bedside plans are severely limited by the lack of validated outcome measures [4]. To facilitate the identification and development of outcome measures for FXS, the NIH organized a panel of experts who evaluated the potential utility of cognitive, behavioral and emotional measures; blood and tissue biomarkers; electrophysiological measures; eye tracking and pupillometry; and neuroimaging tests for FXS [4]. They concluded that there is currently no single or set of endpoints that can serve as an optimal biomarker for FXS clinical trials. The Aberrant Behavior Checklist (ABC) is commonly adopted as the primary outcome measure in FXS clinical trials [4],[5]. A recent phase 2 trial conducted by Seaside Therapeutics, Inc. to evaluate the safety and tolerability of the GABA agonist STX209 (R-baclofen) in patients with FXS failed on the primary endpoint, which was the ABC-Irritability subscale, although benefit was observed in other measures mostly by posthoc analysis [6]. Novartis has also terminated development of their lead compound for FXS, the mGluR5 inhibitor Mavoglurant (AFQ056), for not meeting the primary endpoint of improved abnormal behaviors compared to placebo. Thus, validated outcome measures and biomarkers could greatly accelerate drug development for FXS. Although recent publications indicate that auditory processing, expressive language sampling, eye tracking and pupillometry, eyeblink conditioning, the 6-factor structured ABC, markerless motion analysis, and the Pediatric Anxiety Rating Scale–Revised (PARS-R) may be viable outcome measures for FXS clinical trials, these tests require considerably more time and money to perform than a simple blood-based biomarker assay. Below, we discuss candidate blood-based biomarkers for FXS including extracellular-regulated kinase (ERK), phosphoinositide 3-kinase (PI3K), matrix metalloproteinase-9 (MMP-9), and amyloid-beta protein precursor (APP) and catabolites (Figure 1).
Figure 1

Potential blood-based biomarkers for FXS. Candidate blood-based biomarkers for FXS include: extracellular-regulated kinase (ERK), phosphoinositide 3-kinase (PI3K), matrix metalloproteinase-9 (MMP-9), amyloid-beta protein precursor (APP) and catabolites, brain-derived neurotrophic factor (BDNF), p70 ribosomal subunit 6 kinase 1 (S6K1), and cytokine and chemokine profiles.

Extracellular-regulated kinase

ERK is a component of the mitogen-activated protein kinase (MAPK) signal transduction pathway. ERK signaling can be activated by either protein tyrosine-linked receptors or by G protein-coupled receptors with signaling propagated through a series of phosphorylation reactions. Although there are contradictory results regarding basal phospho-ERK levels and mGluR-induced phosphorylation of ERK in FXS models, a specific inhibitor of the upstream mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) eliminated audiogenic seizure activity in Fmr1 KO mice [7]. Findings from the Greenough laboratory suggest that the early phase kinetics of ERK activation in lymphocytes is delayed in FXS subjects and could serve as a disease biomarker [8]. ERK activation rates normalize in response to lithium and riluzole treatment [9],[10].

Phosphoinositide 3-kinase

PI3Ks are a family of enzymes involved in cell growth, proliferation, differentiation, motility, survival and intracellular trafficking. The catalytic p110β subunit of class I PI3Ks activates protein kinase B (PKB, aka Akt), which is part of the mammalian target of rapamycin (mTOR) signaling pathway. The Zukin laboratory has shown that p110β as well as mTOR phosphorylation and activity are elevated in juvenile Fmr1 KO mice [11]. Gross and Bassell demonstrated that FMRP regulates the synthesis of p110β and that peripheral lymphocytes from FXS patients exhibit excessive PI3K activity as well as protein synthesis levels [12]. They utilized an ELISA-based colorimetric assay to detect PI3K activity and a fluorescent metabolic labeling assay to detect protein synthesis in FXS lymphocytes. Both methods could be adapted for clinical evaluation of PI3K activity and protein synthesis levels in FXS lymphocytes in response to drug treatment.

Matrix metalloproteinase 9

MMPs are involved in the breakdown of the extracellular matrix during processes such as embryonic development, wound healing and learning and memory. MMP-9 is involved in activity-dependent reorganization of dendritic spine architecture. MMP-9 mRNA is part of the FMRP complex, and translation of MMP-9 is increased at Fmr1 KO synapses [13]. The Ethell laboratory found that the antibiotic minocycline decreases MMP-9 in the hippocampus of Fmr1 KO mice while promoting dendritic spine maturation and improving anxiety and strategic exploratory behavior [14]. Minocycline also prevents all neuroanatomical defects in FXS flies and improves language and social communication skills, anxiety, attention, irritability, stereotypy, hyperactivity and inappropriate speech in humans [15]–[17]. The pro- and active-forms of plasma MMP-9 are substantially elevated in FXS individuals compared to typically developing age-matched controls although a significant overall correlation between reduced MMP-9 activity and observed improvement in the Clinical Global Impression-Improvement (CGI-I) was not observed [18]. The preliminary analysis consisted of plasma samples from ten subjects who received minocycline for 3 months with blood samples collected at baseline and after treatment. Six of the ten subjects exhibited some decrease in MMP-9 activity after minocycline treatment and the remaining four showed no change. Five of six patients with decreased MMP-9 activity exhibited improvement in the CGI-I. Thus, a larger study is required to determine if MMP-9 is a viable blood-based biomarker to monitor minocycline efficacy in FXS.

Amyloid-beta protein precursor and Amyloid-beta

APP and metabolites including amyloid-beta (Aβ) are potential FXS biomarkers. We found that FMRP binds to and regulates the translation of App mRNA [19]. In the absence of FMRP (Fmr1 KO mice), APP and Aβ are overexpressed. Genetic knockout of one App allele in the Fmr1 KO mice rescues many disease phenotypes including seizures, anxiety, the ratio of mature versus immature dendritic spines and mGluR-LTD [20]. In human blood plasma, the level of Aβ1-42 was significantly reduced in full-mutation FXS adult males compared to age-matched controls while APP and Aβ1-40 levels were not altered. These data suggest that Aβ1-42 may be a plausible blood-based biomarker for FXS. APP and Aβ are currently under evaluation as blood-based biomarkers in a prospective open-label trial of acamprosate in FXS youth and preliminary results indicate that APP levels are normalized in response to drug treatment [4]. Accumulating evidence from the Lahiri laboratory shows that Aβ1-40, Aβ1-42 and sAPPβ levels are decreased in plasma of youth with severe autism compared to controls whereas sAPPα levels are elevated [21]. In total, these data suggest that there may be age-dependent differences in APP expression and processing and that these proteins may be valuable biomarkers for both FXS and autism. An important caveat in developing Aβ as a blood-based biomarker is that anticoagulants appear to alter APP processing; thus, blood collection procedures need to be standardized [22]. The advantage of APP and Aβ as blood-based biomarkers for FXS, as opposed to measuring the activity of the aforementioned signaling molecules, is the stability of the proteins in serum.

Other potential biomarkers

In addition to the biomarkers discussed above, other potential candidates include brain-derived neurotrophic factor (BDNF), p70 ribosomal subunit 6 kinase 1 (S6K1), and cytokine and chemokine profiles. Erickson and colleagues observed increased BDNF levels in a pilot FXS trial testing acamprosate [23]. Hoeffer and colleagues found increased phosphorylation of S6K1 in FXS lymphocytes [24]. Ashwood and colleagues found altered plasma cytokine and chemokine levels in FXS subjects; specifically, they observed elevated interleukin-1 alpha (IL-1α), regulated on activation normal T-cell expressed and secreted protein (RANTES) and 10 kDa interferon gamma-induced protein (IP-10) compared to typically developing controls [25].

Summary and conclusions

In summary, there are numerous drugs exhibiting promise in preclinical testing for FXS but no validated blood-based biomarkers or behavioral outcome measures for drug efficacy testing. This mini-review highlights research findings demonstrating that ERK activation rates, PI3K and MMP-9 activity levels, and APP and metabolite levels are potential blood-based biomarkers for FXS. These candidate biomarkers are at early stages of validation and deserve further investigation.

Abbreviations

Aβ: 

Amyloid-beta

ABC: 

Aberrant behavior checklist

APP: 

Amyloid-beta protein precursor

BDNF: 

Brain-derived neurotrophic factor

CGI-I: 

Clinical global impression-improvement

ERK: 

Extracellular-regulated kinase

FMR1

Fragile X mental retardation-1 gene

FMRP: 

Fragile X mental retardation protein

FXS: 

Fragile X syndrome

IL-1α: 

Interleukin-1 alpha

IP-10: 

10 kDa interferon gamma-induced protein

LTD: 

Long-term depression

MAPK: 

Mitogen-activated protein kinase

MEK: 

Mitogen-activated protein kinase kinase

mGluR: 

Metabotropic glutamate receptor

MMP-9: 

Matrix metalloproteinase 9

mTOR: 

Mammalian target of rapamycin

PARS-R: 

Pediatric anxiety rating scale-revised

PI3K: 

Phosphoinositide 3-kinase

PKB: 

Protein kinase B

RANTES: 

Regulated on activation normal T-cell expressed and secreted protein

S6K1: 

p70 ribosomal subunit 6 kinase 1

Declarations

Acknowledgements

This work was supported by NIH HD075881, NIH AG044714 and FRAXA Research Foundation. Funding bodies had no role in the writing of the manuscript or the decision to submit for publication.

Authors’ Affiliations

(1)
Department of Neurology, University of Wisconsin-Madison

References

  1. Hagerman PJ: The fragile X prevalence paradox. J Med Genet 2008, 45(8):498–499. 10.1136/jmg.2008.059055View ArticleGoogle Scholar
  2. Fragile X syndrome: diagnosis, treatment, and research. John Hopkins University Press, Baltimore; 2002.Google Scholar
  3. Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental retardation. Trends Neurosci 2004, 27(7):370–377. 10.1016/j.tins.2004.04.009View ArticleGoogle Scholar
  4. Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK: Outcome measures for clinical trials in fragile x syndrome. J Dev Behav Pediatr 2013, 34(7):508–522. 10.1097/DBP.0b013e31829d1f20View ArticleGoogle Scholar
  5. Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, Berry-Kravis E, Lachiewicz A, Brown EC, Hessl D: Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord 2012, 42(7):1377–1392. 10.1007/s10803-011-1370-2View ArticleGoogle Scholar
  6. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ: Effects of STX209 (Arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase trial. Sci Transl Med 2012, 4(152):127. 10.1126/scitranslmed.3004214View ArticleGoogle Scholar
  7. Wang X, Snape M, Klann E, Stone JG, Singh A, Petersen RB, Castellani RJ, Casadesus G, Smith MA, Zhu X: Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile X-syndrome. J Neurochem 2012, 121(4):672–679. 10.1111/j.1471-4159.2012.07722.xView ArticleGoogle Scholar
  8. Weng N, Weiler IJ, Sumis A, Berry-Kravis E, Greenough WT: Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am J Med Genet B Neuropsychiatr Genet 2008, 147B(7):1253–1257. 10.1002/ajmg.b.30765View ArticleGoogle Scholar
  9. Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT: Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008, 29(4):293–302. 10.1097/DBP.0b013e31817dc447View ArticleGoogle Scholar
  10. Erickson CA, Weng N, Weiler IJ, Greenough WT, Stigler KA, Wink LK, McDougle CJ: Open-label riluzole in fragile X syndrome. Brain Res 2011, 1380: 264–270. 10.1016/j.brainres.2010.10.108View ArticleGoogle Scholar
  11. Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, Zukin RS: Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010, 30(2):694–702. 10.1523/JNEUROSCI.3696-09.2010View ArticleGoogle Scholar
  12. Gross C, Bassell GJ: Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110beta-selective inhibitor. Mol Med 2012, 18: 336–345. 10.2119/molmed.2011.00363View ArticleGoogle Scholar
  13. Janusz A, Milek J, Perycz M, Pacini L, Bagni C, Kaczmarek L, Dziembowska M: The fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses. J Neurosci 2013, 33(46):18234–18241. 10.1523/JNEUROSCI.2207-13.2013View ArticleGoogle Scholar
  14. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM: Minocycline promotes dendritic spine maturation and improves behavioral performance in the fragile X mouse model. J Med Genet 2009, 46(2):94–102. 10.1136/jmg.2008.061796View ArticleGoogle Scholar
  15. Siller SS, Broadie K: Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome. Neural Plast 2012, 2012: 124548.Google Scholar
  16. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW: Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010, 10: 91. 10.1186/1471-2377-10-91View ArticleGoogle Scholar
  17. Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ: A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr 2013, 34(3):147–155. 10.1097/DBP.0b013e318287cd17View ArticleGoogle Scholar
  18. Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, Durbin-Johnson B, Hagerman RJ, Tassone F: High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 2013, 161A(8):1897–1903. 10.1002/ajmg.a.36023View ArticleGoogle Scholar
  19. Westmark CJ, Malter JS: FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol 2007, 5(3):e52. 10.1371/journal.pbio.0050052View ArticleGoogle Scholar
  20. Westmark CJ, Westmark PR, O’Riordan KJ, Ray BC, Hervey CM, Salamat MS, Abozeid SH, Stein KM, Stodola LA, Tranfaglia M, Burger C, Berry-Kravis EM, Malter JS: Reversal of fragile X phenotypes by manipulation of AbetaPP/Abeta levels in Fmr1KO mice. PLoS One 2011, 6(10):e26549. 10.1371/journal.pone.0026549View ArticleGoogle Scholar
  21. Ray B, Long JM, Sokol DK, Lahiri DK: Increased secreted amyloid precursor protein-alpha (sAPPalpha) in severe autism: proposal of a specific, anabolic pathway and putative biomarker. PLoS One 2011, 6(6):e20405. 10.1371/journal.pone.0020405View ArticleGoogle Scholar
  22. Westmark CJ, Hervey CM, Berry-Kravis EM, Malter JS: Effect of anticoagulants on amyloid beta-protein precursor and amyloid beta levels in plasma. Alzheimer's Disease and Parkinsonism 2011, 1(1):1–3.Google Scholar
  23. Erickson CA, Wink LK, Ray B, Early MC, Stiegelmeyer E, Mathieu-Frasier L, Patrick V, Lahiri DK, McDougle CJ: Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 2013, 228(1):75–84. 10.1007/s00213-013-3022-zView ArticleGoogle Scholar
  24. Hoeffer CA, Sanchez E, Hagerman RJ, Mu Y, Nguyen DV, Wong H, Whelan AM, Zukin RS, Klann E, Tassone F: Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with Fragile X syndrome. Genes Brain Behav 2012, 11(3):332–341. 10.1111/j.1601-183X.2012.00768.xView ArticleGoogle Scholar
  25. Ashwood P, Nguyen DV, Hessl D, Hagerman RJ, Tassone F: Plasma cytokine profiles in fragile X subjects: is there a role for cytokines in the pathogenesis? Brain Behav Immun 2010, 24(6):898–902. 10.1016/j.bbi.2010.01.008View ArticleGoogle Scholar

Copyright

© Westmark; licensee Springer 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.